Amendment No. 1 to Strategic Collaboration AgreementStrategic Collaboration Agreement • December 16th, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 (the “Amendment”), effective as of October 18, 2021 (the “Amendment Date”), amends certain provisions of the Strategic Collaboration Agreement dated November 5, 2020 (the “Agreement”), between Affimed GmbH, a German corporation having its principal office at Im Neuenheimer Feld 582, 69120 Heidelberg, Germany (“Affimed”) and Artiva Biotherapeutics, Inc., a US corporation having its principal office at, 4747 Executive Drive #1150, San Diego, CA 92121, USA (“Artiva”), (Affimed and Artiva each a “Party” and together the “Parties”).
October 15, 2021 VIA EMAIL Thomas J. Farrell Founder & Chief Strategy Officer Re: Separation Agreement Dear Tom:Separation Agreement • December 16th, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
This letter sets forth the substance of our agreement (the “Agreement”) regarding your transition and separation from Artiva Biotherapeutics, Inc. (the “Company”). This Agreement will become effective only upon the Effective Date specified in Section 9 below.
